American Journal of Gastroenterology Publishes Key Study Further Validating Esopredict® as a Prognostic Test for Barrett's Esophagus

BALTIMORE, Feb. 12, 2025 /PRNewswire/ -- Today, Previse, a gastrointestinal health company, announced a newly published study in the American Journal of Gastroenterology, which provides additional clinical validation of Esopredict^®, the only commercially available test that uses DNA methylation to assess the risk of future neoplastic progression in patients with precancerous Barrett's esophagus. These findings reinforce Esopredict's value in clinical decision-making, supporting earlier intervention for high-risk patients while reducing unnecessary procedures for those at low risk.

In this publication, titled Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Barrett's Esophagus Patients, Esopredict was performed at multiple locations and time points within each patient. For example, during one endoscopy, biopsies were obtained at different locations within the Barrett's esophagus segment (spatial/location). Regardless of where the biopsy was obtained, Esopredict's performance was similar. Likewise, endoscopies were performed at periodic intervals in each patient (temporal/time point). Regardless of when the biopsy was obtained, Esopredict's performance was similar. Thus, this study establishes Esopredict's robustness regardless of which biopsy is used from a patient's endoscopy, both spatially and temporally.

"Gastroenterologists have expressed the need for a more precise way to identify which Barrett's patients are truly at risk of developing esophageal cancer," said Sarah Laun, Ph.D., Vice President of Research and Development at Previse. "This study confirms that Esopredict provides actionable insights that can help optimize patient management and improve outcomes for patients living with Barrett's esophagus."

"Barrett's esophagus is the only known precursor to esophageal adenocarcinoma (EAC), a highly lethal cancer with increasing incidence rates. At Previse, we are focused on rigorous research that supports better patient outcomes. This study marks a critical advancement for Esopredict in the field of Barrett's esophagus care and management as an effective risk stratification solution," said Daniel Lunz, Chief Executive Officer at Previse.

For more information about Esopredict and the study, visit www.previsedx.com or contact the Previse team at [email protected].

About Previse and Esopredict

Established in 2018, Previse is a gastrointestinal health company with a primary focus on chronic acid reflux-related diseases, including esophageal cancer. Previse's mission is to save lives and improve patient health through prevention and early detection. The company leverages groundbreaking biomarker technology developed by Stephen Meltzer, M.D., and his GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. This technology, backed by funding from the National Institutes of Health (NIH) and decades of research, forms the foundation of Previse's commitment to combating GI diseases, including cancer.

At the forefront is Esopredict, a highly sensitive epigenetic test designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with precancerous Barrett's esophagus. With a turnaround time of about two weeks after a sample is received, Esopredict empowers gastroenterologists to tailor effective treatment strategies, marking a pivotal advancement in the battle against esophageal cancer.

SOURCE Previse